Arrhythmic Risk Stratification among Patients with Hypertrophic Cardiomyopathy
暂无分享,去创建一个
N. Brunetti | F. Santoro | M. Correale | G. Casavecchia | A. Mallardi | M. Gravina | Federica Mango | Damiano D’Alessandro
[1] B. Maron,et al. A novel patient-patient network medicine approach to refine hypertrophic cardiomyopathy subgrouping: implications for risk stratification. , 2023, Cardiovascular Research.
[2] P. Lambiase,et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. , 2022, European heart journal.
[3] R. Omar,et al. External validation of the HCM Risk-Kids model for predicting sudden cardiac death in childhood hypertrophic cardiomyopathy , 2021, European journal of preventive cardiology.
[4] W. Su,et al. Risk factors of sudden cardiac death in hypertrophic cardiomyopathy , 2021, Current opinion in cardiology.
[5] R. Perea,et al. Scar channels in cardiac magnetic resonance to predict appropriate therapies in primary prevention. , 2021, Heart rhythm.
[6] L. Ngo,et al. Machine learning phenotyping of scarred myocardium from cine in hypertrophic cardiomyopathy. , 2021, European heart journal cardiovascular Imaging.
[7] R. Steeds,et al. Transthoracic echocardiography of hypertrophic cardiomyopathy in adults: a practical guideline from the British Society of Echocardiography , 2021, Echo research and practice.
[8] M. Gawaz,et al. Long-term risk of sudden cardiac death in hypertrophic cardiomyopathy: a cardiac magnetic resonance outcome study , 2021, European heart journal cardiovascular Imaging.
[9] M. Guazzi,et al. Risk stratification in cardiomyopathy , 2020, European journal of preventive cardiology.
[10] Matthew W. Martinez,et al. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. , 2020, Circulation.
[11] G. T. Gunnarsson,et al. 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease. , 2020, European heart journal.
[12] S. Solomon,et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial , 2020, The Lancet.
[13] H. Rakowski,et al. Primary Prevention Implantable Cardioverter Defibrillators in Hypertrophic Cardiomyopathy - Are There Predictors of Appropriate Therapy? , 2020, Heart rhythm.
[14] G. MacGowan,et al. Genetic determinants of clinical phenotype in hypertrophic cardiomyopathy , 2020, BMC Cardiovascular Disorders.
[15] S. Qiao,et al. Quantitative fragmented QRS has a good diagnostic value on myocardial fibrosis in hypertrophic obstructive cardiomyopathy based on clinical-pathological study , 2020, BMC Cardiovascular Disorders.
[16] C. Ki,et al. Genotype-Related Clinical Characteristics and Myocardial Fibrosis and Their Association with Prognosis in Hypertrophic Cardiomyopathy , 2020, Journal of clinical medicine.
[17] R. Weintraub,et al. Development of a Novel Risk Prediction Model for Sudden Cardiac Death in Childhood Hypertrophic Cardiomyopathy (HCM Risk-Kids). , 2019, JAMA cardiology.
[18] H. Rakowski,et al. Evaluation of Hypertrophic Cardiomyopathy: Newer Echo and MRI Approaches , 2019, Current Cardiology Reports.
[19] E. Ashley,et al. Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy , 2018, Circulation.
[20] A. García-Álvarez,et al. Hypertrophic cardiomyopathy: Sudden cardiac death risk stratification in adults , 2018, Global cardiology science & practice.
[21] Sinem Özyılmaz,et al. Assessment of the relationship between the ambulatory electrocardiography-based micro T-wave alternans and the predicted risk score of sudden cardiac death at 5 years in patients with hypertrophic cardiomyopathy , 2018, Anatolian journal of cardiology.
[22] B. Gersh,et al. Hypertrophic Cardiomyopathy: Clinical Update. , 2018, JACC. Heart failure.
[23] I. Kallikazaros,et al. Programmed ventricular stimulation predicts arrhythmic events and survival in hypertrophic cardiomyopathy. , 2018, International journal of cardiology.
[24] Z. Oko-Sarnowska,et al. Sudden Cardiac Death in Hypertrophic Cardiomyopathy. , 2017, Cardiology in review.
[25] P. Sorajja. Alcohol Septal Ablation for Obstructive Hypertrophic Cardiomyopathy: A Word of Balance. , 2017, Journal of the American College of Cardiology.
[26] D. Aras,et al. Tp-e interval and Tp-e/QTc ratio as novel surrogate markers for prediction of ventricular arrhythmic events in hypertrophic cardiomyopathy , 2017, Anatolian journal of cardiology.
[27] M. Link,et al. Prognostic Implications of Nonsustained Ventricular Tachycardia in High-Risk Patients With Hypertrophic Cardiomyopathy , 2017, Circulation. Arrhythmia and electrophysiology.
[28] C. Autore,et al. Cardiopulmonary exercise test and sudden cardiac death risk in hypertrophic cardiomyopathy , 2016, Heart.
[29] K. Hayashi,et al. Electrocardiographic QRS Fragmentation as a Marker for Myocardial Fibrosis in Hypertrophic Cardiomyopathy , 2015, Journal of cardiovascular electrophysiology.
[30] B. Maron,et al. Independent Assessment of the European Society of Cardiology Sudden Death Risk Model for Hypertrophic Cardiomyopathy. , 2015, The American journal of cardiology.
[31] F. T. ten Cate,et al. Validation of the 2014 European Society of Cardiology Guidelines Risk Prediction Model for the Primary Prevention of Sudden Cardiac Death in Hypertrophic Cardiomyopathy , 2015, Circulation. Arrhythmia and electrophysiology.
[32] Milind Y Desai,et al. Predictors of long-term outcomes in patients with hypertrophic cardiomyopathy undergoing cardiopulmonary stress testing and echocardiography. , 2015, American heart journal.
[33] Barry J Maron,et al. New perspectives on the prevalence of hypertrophic cardiomyopathy. , 2015, Journal of the American College of Cardiology.
[34] F. Rutten,et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). , 2014, European heart journal.
[35] Ajit H. Janardhan,et al. Fragmented QRS as a candidate marker for high-risk assessment in hypertrophic cardiomyopathy. , 2014, Heart rhythm.
[36] B. Gorenek,et al. Fragmented QRS as a predictor of arrhythmic events in patients with hypertrophic obstructive cardiomyopathy , 2013, Journal of Interventional Cardiac Electrophysiology.
[37] P. Elliott,et al. Sudden cardiac death in hypertrophic cardiomyopathy. , 2013, Circulation. Arrhythmia and electrophysiology.
[38] Barry J Maron,et al. 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: Executive Summary A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines , 2011, Circulation.
[39] S. Matsuoka,et al. Impairment of ubiquitin-proteasome system by E334K cMyBPC modifies channel proteins, leading to electrophysiological dysfunction. , 2011, Journal of molecular biology.
[40] A. Rynkiewicz,et al. Sudden death in hypertrophic cardiomyopathy: old risk factors re-assessed in a new model of maximalized follow-up. , 2010, European heart journal.
[41] G. Bonsel,et al. Risk stratification for sudden cardiac death in hypertrophic cardiomyopathy: systematic review of clinical risk markers. , 2010, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[42] L. Monserrat,et al. Severe cardiac conduction disturbances and pacemaker implantation in patients with hypertrophic cardiomyopathy. , 2010, Revista espanola de cardiologia.
[43] G. Giannakoulas,et al. Left ventricular outflow tract obstruction as a risk factor for sudden cardiac death in hypertrophic cardiomyopathy. , 2009, The American journal of cardiology.
[44] G. Giannakoulas,et al. Identification of high risk patients with hypertrophic cardiomyopathy in a northern Greek population , 2009, Cardiovascular Ultrasound.
[45] J. Hodges,et al. Long-term survival after cardiac arrest in hypertrophic cardiomyopathy. , 2009, Heart rhythm.
[46] C. Autore,et al. Syncope and Risk of Sudden Death in Hypertrophic Cardiomyopathy , 2009, Circulation.
[47] B. Maron,et al. Sudden Deaths in Young Competitive Athletes: Analysis of 1866 Deaths in the United States, 1980–2006 , 2009, Circulation.
[48] Veniamin Y Sidorov,et al. Myofilament Ca2+ sensitization causes susceptibility to cardiac arrhythmia in mice. , 2008, The Journal of clinical investigation.
[49] Eloisa Arbustini,et al. Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. , 2007, European heart journal.
[50] P. Elliott,et al. Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy. , 2006, European heart journal.
[51] R. Hui,et al. Prevalence of idiopathic hypertrophic cardiomyopathy in China: a population-based echocardiographic analysis of 8080 adults. , 2004, The American journal of medicine.
[52] C. Tracy,et al. American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice G , 2003, European heart journal.
[53] P. Elliott,et al. Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. , 2003, Journal of the American College of Cardiology.
[54] P. Elliott,et al. Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy , 2001, The Lancet.
[55] P. Elliott,et al. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. , 2000, Journal of the American College of Cardiology.
[56] M. Link,et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. , 2000, The New England journal of medicine.
[57] M. Komajda,et al. Clinical features and prognostic implications of familial hypertrophic cardiomyopathy related to the cardiac myosin-binding protein C gene. , 1998, Circulation.
[58] H Niimura,et al. Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. , 1998, The New England journal of medicine.
[59] W. Mckenna,et al. Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy. , 1997, Circulation.
[60] N. Severs,et al. Altered patterns of cardiac intercellular junction distribution in hypertrophic cardiomyopathy. , 1996, Heart.
[61] L. Fananapazir,et al. Prevalence of hypertrophic cardiomyopathy and limitations of screening methods. , 1995, Circulation.
[62] C. Autore,et al. Prognosis of Asymptomatic Patients With Hypertrophic Cardiomyopathy and Nonsustained Ventricular Tachycardia , 1994, Circulation.
[63] O. Ratib,et al. Regional Myocardial Blood Flow and Glucose Utilization in Symptomatic Patients With Hypertrophic Cardiomyopathy , 1993, Circulation.
[64] D. Webb,et al. Abnormal Vascular Responses to Supine Exercise in Hypertrophic Cardiomyopathy , 1991, Circulation.
[65] K. Kuck,et al. Programmed electrical stimulation in hypertrophic cardiomyopathy. Results in patients with and without cardiac arrest or syncope. , 1988, European heart journal.
[66] M. Josephson,et al. Inducible polymorphic ventricular tachycardia and ventricular fibrillation in a subgroup of patients with hypertrophic cardiomyopathy at high risk for sudden death. , 1987, Journal of the American College of Cardiology.
[67] W. Stevenson,et al. Value of programmed electrical stimulation using a standardized ventricular stimulation protocol in hypertrophic cardiomyopathy. , 1987, The American journal of cardiology.
[68] R. Sterba,et al. Electrophysiologic Studies of Patients with Hypertrophic Cardiomyopathy Presenting with Syncope of Undetermined Etiology * , 1986, Pacing and clinical electrophysiology : PACE.
[69] B. Maron,et al. Prognostic significance of 24 hour ambulatory electrocardiographic monitoring in patients with hypertrophic cardiomyopathy: a prospective study. , 1981, The American journal of cardiology.
[70] W. Mckenna,et al. Arrhythmia in hypertrophic cardiomyopathy. I: Influence on prognosis. , 1981, British heart journal.
[71] W. Mckenna,et al. Prognosis in hypertrophic cardiomyopathy: role of age and clinical, electrocardiographic and hemodynamic features. , 1981, The American journal of cardiology.
[72] B. Maron,et al. Prevalence of arrhythmias during 24-hour electrocardiographic monitoring and exercise testing in patients with obstructive and nonobstructive hypertrophic cardiomyopathy. , 1979, Circulation.